Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07255898 | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07490613 | A Phase I Study of SHR-3836 in Patients With Multiple Myeloma | recruiting | Phase 1 | 99 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07528352 | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL(REBEL) | recruiting | Phase 1 | 12 | University of UtahOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07581704 | Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma | recruiting | Phase 1 | 10 | Christopher StrouseOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05625594 | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05848687 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | recruiting | Phase 1 / Phase 2 | 90 | Tanja Andrea GruberOTHER | 2 | Jun 3, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | recruiting | Phase 1 | 54 | Sumithira VasuOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03219450 | A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease(KOALA) | recruiting | Phase 1 | 12 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | recruiting | Phase 1 / Phase 2 | 115 | Stephan Grupp MD PhDOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07001384 | A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02443831 | CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia | recruiting | Phase 1 | 50 | University College, LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05685173 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas(ATHENA-1) | recruiting | Phase 1 | 107 | Regeneron PharmaceuticalsINDUSTRY | 5 | May 19, 2026 | clinicaltrials |
| NCT06433947 | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 130 | Opna Bio LLCINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06777979 | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05853965 | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma(BELI(E)VE) | recruiting | Phase 1 / Phase 2 | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07220993 | Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | recruiting | Phase 1 | 20 | Juan P. Alderuccio, MDOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06879340 | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 54 | University of Kansas Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment(LINKER-MM4) | recruiting | Phase 1 / Phase 2 | 149 | Regeneron PharmaceuticalsINDUSTRY | 3 | May 13, 2026 | clinicaltrials |
| NCT06223542 | Studying TAK-243 in Patients With Advanced Cancer | recruiting | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies(CAR-p40-T) | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07225985 | Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06481735 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | recruiting | Phase 1 / Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07377435 | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06874946 | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07093073 | Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma | recruiting | Phase 1 | 30 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07249905 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | recruiting | Phase 1 / Phase 2 | 180 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07283679 | Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05984147 | A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)(ASHA-1) | recruiting | Phase 1 | 40 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07496229 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | recruiting | Phase 1 / Phase 2 | 165 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT06378190 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology(TranspoCART19) | recruiting | Phase 1 / Phase 2 | 27 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06484777 | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma | recruiting | Phase 1 | 138 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | recruiting | Phase 1 / Phase 2 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2026source: clinicaltrials